1. HPV self-testing for primary cervical cancer screening in Madagascar: VIA/VILI triage compliance in HPV-positive women
- Author
-
Patrick Petignat, Joséa Lea Herniainasolo, Pierre Vassilakos, Jeromine Jinoro, Rosa Catarino, Milena Alec, Anne-Caroline Benski, and Manuela Viviano
- Subjects
Viral Diseases ,Critical Care and Emergency Medicine ,Biopsy ,Uterine Cervical Neoplasms ,Cervix Uteri ,Cervical cancer screening ,Pathology and Laboratory Medicine ,0302 clinical medicine ,Medicine and Health Sciences ,030212 general & internal medicine ,Papillomavirus Infections/complications ,Early Detection of Cancer ,Multidisciplinary ,ddc:618 ,medicine.diagnostic_test ,Middle Aged ,Hpv testing ,Chemistry ,Infectious Diseases ,Oncology ,Medical Microbiology ,030220 oncology & carcinogenesis ,Viral Pathogens ,Viruses ,Physical Sciences ,Medicine ,Engineering and Technology ,Female ,Pathogens ,Cancer Screening ,Research Article ,Chemical Elements ,Iodine ,Quality Control ,Adult ,medicine.medical_specialty ,Human Papillomavirus Infection ,Papillomaviruses ,Science ,Urology ,Group ii ,Visual Inspection ,Sexually Transmitted Diseases ,Surgical and Invasive Medical Procedures ,Microbiology ,HPV-16 ,03 medical and health sciences ,Cervical intraepithelial neoplasia grade 2 ,Diagnostic Medicine ,Internal medicine ,mental disorders ,Industrial Engineering ,medicine ,Cancer Detection and Diagnosis ,Madagascar ,Humans ,Systematic biopsy ,Microbial Pathogens ,Aged ,Early Detection of Cancer/methods/psychology/statistics & numerical data ,Biology and life sciences ,business.industry ,Madagascar/epidemiology ,Genitourinary Infections ,HPV Positive ,Uterine Cervical Neoplasms/diagnosis/pathology/virology ,Papillomavirus Infections ,Organisms ,Human Papillomavirus ,Triage ,Cervix Uteri/pathology ,Patient Compliance/psychology/statistics & numerical data ,Self Care ,Self Care/psychology/statistics & numerical data ,Patient Compliance ,business ,DNA viruses - Abstract
ObjectiveTo assess triage compliance and the effect of the time from screening to triage on follow-up among HPV-positive women.MethodsWe recruited 1232 women in a screening campaign in Madagascar from February to October 2015. In the first period (February-May), HPV tests were performed remotely using the cobas test. In the second period (May-October), testing was performed on-site using the Xpert HPV assay. HPV-positive women were invited for triage with visual inspection with acetic acid (VIA) and Lugol's iodine (VILI). Systematic biopsy and endocervical brushing were performed on all HPV-positive women for quality control. Three groups were defined according to time from HPV testing to triage invitation for HPV-positive women-Group I: delayed (> 3 months), Group II: prompt (24-48 hours), and Group III: immediate (< 24 hours).ResultsA total 1232 self-sampled HPV tests were performed in the study period (496 in Group I, 512 in Group II, and 224 in Group III). Participants' mean age was 43.2 ± 9.3 years. Mean time from screening to VIA/VILI testing was 103.5 ± 43.6 days. Overall HPV prevalence was 28.0%. HPV prevalence was 27.2% in Group I (cobas test), 29.2% in Group 2 (Xpert test), and 26,7% in Group III (Xpert test). The VIA/VILI compliance rate was 77.8% for Group I, 82.7% for Group II, and 95.0% for Group III. Of women undergoing VIA/VILI, 56.3% in Group I and 43.5% in Groups II/III had positive results. Prevalence of cervical intraepithelial neoplasia grade 2 or worse among HPV-positive women was 9.8% for Group I and 6.8% for Groups II/III. Non-adherence was higher among rural women, uneducated women, and women in Group I.ConclusionHPV-positive women with immediate VIA/VILI triage invitation had the best triage compliance. A single-day test and triage strategy is preferred for low-resource settings.
- Published
- 2019